Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Middleby forecasts 2026 adjusted EPS of $7.13-$7.29

Middleby forecasts 2026 adjusted EPS of $7.13-$7.29

BitgetBitget2026/11/05 12:25
  • Middleby forecasts fiscal 2026 adjusted EPS of USD 7.13-7.29, up 18.1% at the midpoint.
  • Full-year sales guidance is USD 2.52-2.53 billion, with adjusted EBITDA of USD 589-593 million.
  • Fourth-quarter adjusted EPS is projected at USD 1.76-1.92, with sales of USD 621-635 million.
  • Quarterly adjusted EBITDA is forecast at USD 149-153 million, supported by operational improvements and pricing gains.
  • Third-quarter adjusted EPS reached USD 2.07, exceeding guidance of USD 1.67-1.83 as higher revenue and share repurchases supported earnings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Middleby Corporation published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss